1. Steroid exposure and outcome in COVID-19 pneumonia
- Author
-
Christopher Remmington, Nicholas A Barrett, Sangita Agarwal, Boris Lams, Patrick Collins, Valentina Camarda, Chris Meadows, Fraser Hanks, Barnaby Sanderson, Andrew Retter, and Luigi Camporota
- Subjects
acute respiratory distress syndrome ,corticosteroid ,COVID-19 ,mechanical ventilation ,steroid ,Anesthesiology ,RD78.3-87.3 - Abstract
Background: Corticosteroids are used to treat COVID-19 pneumonia. However, the optimal dose is unclear. This study describes the association between corticosteroid exposure with disease severity and outcome in COVID-19 pneumonia. Methods: This is a single-centre retrospective, observational study including adult ICU patients who received systemic corticosteroids for COVID-19 pneumonia between March 2020 and March 2021. We recorded patient characteristics, disease severity, total steroid exposure, respiratory support and gas exchange data, and 90-day mortality. Results: We included 362 patients. We allocated patients to groups with increasing disease severity according to the highest level of respiratory support that they received: high-flow nasal oxygen or continuous positive airway pressure (HFNO/CPAP) in 12.7%, invasive mechanical ventilation (IMV) in 61.6%, and extracorporeal membrane oxygenation (ECMO) in 25.7%. For these three groups, the median (inter-quartile range [IQR]) age was 61 (54–71) vs 58 (50–66) vs 46 (38–53) yr, respectively (P
- Published
- 2023
- Full Text
- View/download PDF